Molecular docking research analysis of novel natural and synthetic PTP 1B inhibitors as potential therapeutic target for diabetes mellitus

Danish Ahmed; Manju Sharma; Vikas Kumar; Pankaj Yadav Subhashchandra

doi:10.1530/endoabs.32.P496

P496

Prev Next

Section Contents Cite

Endocrine Abstracts (2013) 32 P496 | DOI: 10.1530/endoabs.32.P496

ECE2013 Poster Presentations Diabetes (151 abstracts)

Molecular docking research analysis of novel natural and synthetic PTP 1B inhibitors as potential therapeutic target for diabetes mellitus

Danish Ahmed ¹ , Manju Sharma ² , Vikas Kumar ¹ & Pankaj Yadav Subhashchandra ¹

Views

Author affiliations

¹Department of Pharmaceutical Sciences, Faculty of Health Sciences, Sam Higginbottom Institute of Agriculture, Technology and Sciences-Deemed University, Allahabad, India; ²Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard University, New Delhi, India.

Augmented pervasiveness of type 2 diabetes mellitus and obesity has amplified the medical necessitate for new agents to treat these disease states. Both type 2 diabetes and obesity are connected to the resistance to the hormones insulin and leptin. Protein tyrosine phosphatase 1B (PTP1B) has been shown to function as negative regulator of insulin signalling as well as leptin signal transduction. At present there are copious compounds synthesized as PTP1B inhibitors. The development of compound libraries with more selective PTP1B inhibitors has been bumped up by the realization that many natural products have PTP1B inhibitory activity and therefore are attention-grabbing biologically lead compounds. This research exertion shows the molecular docking analysis of novel synthetically prepared compounds and new-fangled isolated natural PTP 1B inhibitors as novel target for type 2 diabetes.

Figure 1 Negative Regulation of Insulin and Leptin Pathways by PTP 1B